全文获取类型
收费全文 | 6105篇 |
免费 | 330篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 161篇 |
儿科学 | 114篇 |
妇产科学 | 162篇 |
基础医学 | 832篇 |
口腔科学 | 127篇 |
临床医学 | 445篇 |
内科学 | 1444篇 |
皮肤病学 | 374篇 |
神经病学 | 454篇 |
特种医学 | 277篇 |
外科学 | 884篇 |
综合类 | 54篇 |
预防医学 | 357篇 |
眼科学 | 99篇 |
药学 | 345篇 |
中国医学 | 7篇 |
肿瘤学 | 324篇 |
出版年
2021年 | 76篇 |
2020年 | 46篇 |
2019年 | 70篇 |
2018年 | 93篇 |
2017年 | 62篇 |
2016年 | 100篇 |
2015年 | 113篇 |
2014年 | 148篇 |
2013年 | 174篇 |
2012年 | 263篇 |
2011年 | 266篇 |
2010年 | 152篇 |
2009年 | 165篇 |
2008年 | 258篇 |
2007年 | 293篇 |
2006年 | 256篇 |
2005年 | 265篇 |
2004年 | 272篇 |
2003年 | 265篇 |
2002年 | 217篇 |
2001年 | 187篇 |
2000年 | 235篇 |
1999年 | 230篇 |
1998年 | 74篇 |
1997年 | 58篇 |
1996年 | 50篇 |
1995年 | 38篇 |
1994年 | 36篇 |
1993年 | 41篇 |
1992年 | 93篇 |
1991年 | 108篇 |
1990年 | 106篇 |
1989年 | 125篇 |
1988年 | 94篇 |
1987年 | 81篇 |
1986年 | 79篇 |
1985年 | 70篇 |
1984年 | 53篇 |
1983年 | 42篇 |
1979年 | 54篇 |
1978年 | 40篇 |
1977年 | 38篇 |
1975年 | 46篇 |
1974年 | 47篇 |
1973年 | 55篇 |
1972年 | 43篇 |
1971年 | 46篇 |
1970年 | 37篇 |
1969年 | 37篇 |
1967年 | 33篇 |
排序方式: 共有6460条查询结果,搜索用时 15 毫秒
91.
U. Klaassen H. Wilke A. Harstrick C. Philippou Pari D. Strumberg K. Neumann W. Eberhardt W. Achterrath L. Lenaz S. Seeber 《Annals of oncology》1998,9(1):45-50
Purpose: To evaluate the antitumor activity in terms of response rate (RR), time to progression (TTP) and survival of paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil (5-FU)/leucovorin in pretreated metastatic breast cancer (MBC).Patients and methods: Fifty-four patients with bidimensionally measureable disease were included during phase II. Thirty-two had anthracycline resistant disease. Treatment consisted of 5-FU (24-hour i.v. infusion) 2.0 g/m2, leucovorin (two-hour i.v. infusion prior to 5-FU) 500 mg/m2, weekly for six weeks (day 1, 8, 15, 22, 29, 36) and paclitaxel (three-hour i.v. infusion) 175 mg/m2 was administered additionally on days 1 and 22, q 50 days.Results: We observed complete remissions in 4% of patients (2 of 54), partial remissions in 55% (30 of 54), stable disease in 37% (20 of 54) and progressive disease in 4% (2 of 54). The overall RR was 59% (95% CI 48%–72%). The RR in 32 patients with anthracycline resistant disease was 59% (19 of 32). The median duration of response was 12 months (3–22), median TTP eight months (2–22) and median survival time 15 months (2–28). Neutropenia was common, but of CTC grade 2 or 3 in most patients. Nonhematologic toxicities mostly consisted of CTC grade 1 and 2 myalgia, diarrhea, mucosits, nausea and vomiting.Conclusions: Paclitaxel combined with weekly 24-hour infusional 5-FU/leucovorin is well tolerated in the second line treatment of MBC. High efficacy was documented even in the treatment of anthracycline resistant disease, which warrants further evaluation. 相似文献
92.
93.
94.
Rita Azizi-Egrari Charlotte G. Neumann Linda B. Bourque Gail G. Harrison Marian D. Sigman 《Ecology of food and nutrition》2004,43(5):355-373
Associations between maternal nutritional factors including energy intake, body mass index, postpartum weight change, and anemia status and maternal-infant interactions were examined in 124 mother-infant pairs from a marginally malnourished, rural Kenyan population. Anemic mothers spent less time holding and caring for their infants than nonanemic mothers. Mothers who retained their pregnancy weight gain or were able to gain weight postpartum spent more time looking at their infants than mothers who lost weight postpartum. Maternal food intake per se was not associated with patterns of infant interaction. Lower birth weight infants were held more, cared for more, and looked at face-to-face more by their mothers. Older sisters tended to be more involved in infant interactions with higher birth weight infants. 相似文献
95.
The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer 总被引:8,自引:0,他引:8
Danforth DN Aloj L Carrasquillo JA Bacharach SL Chow C Zujewski J Whatley M Galen B Merino M Neumann RD 《Breast cancer research and treatment》2002,75(2):135-146
Purpose. In women with breast cancer, knowledge of the local/regional extent of the tumor is essential for staging, treatment planning, monitoring response to therapy, and follow-up. Positron emission tomography (PET) is an important imaging test which can detect tumor at multiple sites in women with breast cancer. We compared the ability of PET to provide a comprehensive view of the local/regional extent of tumor in women with stage I, II and stage III, IV breast cancer.
Materials and methods. Forty-six women with breast cancer underwent PET using 18F-FDG. 18FDG uptake in the breast primary tumor, associated skin, axillary and internal mammary lymph nodes, and the contralateral breast was determined qualitatively, and correlated with histologic, clinical and radiographic findings.
Results. Twenty-four patients were premenopausal and 22 were postmenopausal, with the following distribution according to clinical stage: stage I – 2 patients, stage II – 16, stage III – 16, stage IV – 12 patients. Among stage I, II patients, the sensitivity for detection of the primary tumor was 83.3%, and for detection of axillary lymph node metastases was 42.9%. 18FDG-PET was negative for the breast skin, contralateral breast, and internal mammary lymph nodes in all stage I, II patients, in agreement with clinical and radiographic findings. Among 28 stage III, IV patients, the sensitivity of 18FDG-PET for detection of the primary tumor was 90.5%, and for detection of axillary lymph node metastases 83.3%. Fourteen patients had clinically advanced changes in the skin, and the sensitivity of PET for detection of skin changes was 76.9%. 18FDG-PET was positive in the internal mammary lymph nodes in 25.0%, and negative in the contralateral breast in all patients with stage III, IV breast cancer. 18FDG-PET was studied in 10 patients following neoadjuvant chemotherapy, and showed a strong correlation with clinical response, and with clinical and pathological findings post-treatment at multiple local/regional sites.
Conclusion.
18FDG-PET can provide a comprehensive image of local/regional tumor in women with breast cancer. 18FDG-PET may play a greater role in women with stage III, IV breast cancer because of increased sensitivity and the increased involvement of multiple local/regional sites with tumor. 相似文献
96.
97.
Long‐term recurrence of soft tissue sarcomas: Prognostic factors and implications for prolonged follow‐up 下载免费PDF全文
Maud Toulmonde MD Axel Le Cesne MD Jean Mendiboure MSc Jean‐Yves Blay MD PhD Sophie Piperno‐Neumann MD Christine Chevreau MD Corinne Delcambre MD Nicolas Penel MD PhD Philippe Terrier MD Dominique Ranchère‐Vince MD Marick Lae MD Sophie Le Guellec MD Jean‐Jacques Michels MD Yves‐Marie Robin MD Carine Bellera PhD Antoine Italiano MD PhD 《Cancer》2014,120(19):3003-3006
98.
Megan Sheahan Caitlin A. Gould James E. Neumann Patrick L. Kinney Sandra Hoffmann Charles Fant Xinyue Wang Michael Kolian 《Environmental health perspectives》2022,130(8)
Background: This paper represents, to our knowledge, the first national-level (United States) estimate of the economic impacts of vibriosis cases as exacerbated by climate change. Vibriosis is an illness contracted through food- and waterborne exposures to various Vibrio species (e.g., nonV. cholerae O1 and O139 serotypes) found in estuarine and marine environments, including within aquatic life, such as shellfish and finfish.Objectives: The objective of this study was to project climate-induced changes in vibriosis and associated economic impacts in the United States related to changes in sea surface temperatures (SSTs).Methods: For our analysis to identify climate links to vibriosis incidence, we constructed three logistic regression models by Vibrio species, using vibriosis data sourced from the Cholera and Other Vibrio Illness Surveillance system and historical SSTs. We relied on previous estimates of the cost-per-case of vibriosis to estimate future total annual medical costs, lost income from productivity loss, and mortality-related indirect costs throughout the United States. We separately reported results for V. parahaemolyticus, V. vulnificus, V. alginolyticus, and “V. spp.,” given the different associated health burden of each.Results: By 2090, increases in SST are estimated to result in a 51% increase in cases annually relative to the baseline era (centered on 1995) under Representative Concentration Pathway (RCP) 4.5, and a 108% increase under RCP8.5. The cost of these illnesses is projected to reach annually under RCP4.5, and annually under RCP8.5, relative to in the baseline (2018 U.S. dollars), equivalent to 140% and 234% increases respectively.Discussion: Vibriosis incidence is likely to increase in the United States under moderate and unmitigated climate change scenarios through increases in SST, resulting in a substantial burden of morbidity and mortality, and costing billions of dollars. These costs are mostly attributable to deaths, primarily from exposure to V. vulnificus. Evidence suggests that other factors, including sea surface salinity, may contribute to further increases in vibriosis cases in some regions of the United States and should also be investigated. https://doi.org/10.1289/EHP9999a 相似文献
99.
Tanja Bhme Ulrich Beschorner Elias Noory Miriam Molitor Thomas Nührenberg Franz-Josef Neumann Thomas Zeller 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2022,49(6)
BackgroundMeta-analyses of randomized controlled trials have suggested an increased long-term mortality risk following femoropopliteal and infrapopliteal angioplasty using paclitaxel-coated devices. This study was conducted to evaluate long-term mortality after paclitaxel drug-coated balloon (DCB) and plain old balloon angioplasty (POBA) of infrapopliteal lesions in real-world practice.MethodsA retrospective mortality analysis of patients with at least 3 years of follow-up who underwent balloon-based endovascular therapy of infrapopliteal lesions was performed.ResultsOverall, 2,424 patients with infrapopliteal lesions were treated within the study period. Five hundred seventy-six patients fulfilled the study criteria. Of those, 269 patients were treated with uncoated devices without crossover to a paclitaxel-coated device during follow-up and 307 patients with DCB angioplasty. Mean (SD) follow-up was 46.48 (32.77) months. The mortality rate was 66.9% after POBA and 46.9% after DCB (P < .001). In the matched-pair cohort, 164 patients died after uncoated treatment (66.7%), and 119 in the DCB group died (48.4%; P < .001). There was no correlation between DCB length and mortality rate (P = .357). For the entire cohort, multivariate logistic regression analysis showed type of treatment (uncoated device vs DCB; P = .002), age (P < .001), stroke (P = .005), renal insufficiency (P = .014), and critical limb ischemia (P = .001) to be independent predictors of all-cause mortality. There was no significant difference in mortality among the paclitaxel exposure groups.ConclusionIn this real-world retrospective analysis, the long-term mortality rate was lower after DCB angioplasty than after POBA of infrapopliteal lesions. 相似文献
100.
Raisuke Iijima MD Gjin Ndrepepa MD Julinda Mehilli MD Franz-Josef Neumann MD Stefanie Schulz MD Jurriën ten Berg MD Olga Bruskina MD Franz Dotzer MD Josef Dirschinger MD Peter B. Berger MD Albert Schömig MD Adnan Kastrati MD 《Clinical research in cardiology》2008,97(3):160-168
Objective We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes
(ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel.
Methods The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 2) trial included
2,022 patients with non-ST elevation ACS undergoing PCI who were randomized to abciximab or placebo after pretreatment with
600 mg of clopidogrel. The patients were divided into groups with elevated TnT level (n = 1,049) and no elevated TnT level (n = 973). The primary end point of the trial was the composite of death, myocardial infarction and urgent reintervention at
30 days.
Results In patients with elevated TnT level the incidence of the primary end point was 13.1% in the abciximab group Vs. 18.3% in the
placebo group [relative risk (RR): 0.70; 95% confidence interval (CI), 0.52–0.95, P = 0.02]. The combined incidence of death or myocardial infarction was 12.9% in the abciximab group vs. 17.9% in the placebo
group (RR: 0.71; 95% CI, 0.52–0.96, P = 0.03). In contrast, the incidence of the primary end point in patients with no elevated TnT level was identical in both
treatment groups (4.6%). The risk of bleeding was not related to TnT level.
Conclusions Baseline troponin level affects the benefit of abciximab in patients with ACS undergoing PCI after pretreatment with a high
loading dose of clopidogrel. Abciximab reduces the risk of ischemic events only in patients with ACS and elevated troponin
level. 相似文献